Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
NCT ID: NCT01442194
Last Updated: 2022-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3076 participants
OBSERVATIONAL
2011-08-01
2020-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT01497262
Safety and Efficacy of Fingolimod in MS Patients in China
NCT01941004
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
NCT01281657
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT00289978
Impact of Fingolimod Adherence on Outcomes
NCT05141669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fingolimod
non-interventional
Fingolimod
parallel cohort
non-interventional
other disease-modifying therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
other disease-modifying therapy
Fingolimod
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Starting fingolimod at time of study entry.
* Starting another approved DMT or started within maximum 6 months prior to study entry.
* Patients, or a able legal representative of the patient, who are willing to provide written informed consent.
Fingolimod patients will constitute the fingolimod cohort while patients with the other DMT will constitute the parallel cohort
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Cullman, Alabama, United States
Novartis Investigative Site
Mobile, Alabama, United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Sottsdale, Arizona, United States
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Bakersfield, California, United States
Novartis Investigative Site
Banning, California, United States
Novartis Investigative Site
Burbank, California, United States
Novartis Investigative Site
Fresno, California, United States
Novartis Investigative Site
Fullerton, California, United States
Novartis Investigative Site
Huntington Beach, California, United States
Novartis Investigative Site
Irvine, California, United States
Novartis Investigative Site
Loma Linda, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Newport Beach, California, United States
Novartis Investigative Site
Oceanside, California, United States
Novartis Investigative Site
Placentia, California, United States
Novartis Investigative Site
Pomona, California, United States
Novartis Investigative Site
Redding, California, United States
Novartis Investigative Site
Santa Monica, California, United States
Novartis Investigative Site
Temecula, California, United States
Novartis Investigative Site
Aurora, Colorado, United States
Novartis Investigative Site
Basalt, Colorado, United States
Novartis Investigative Site
Colorado Springs, Colorado, United States
Novartis Investigative Site
Denver, Colorado, United States
Novartis Investigative Site
Fort Collins, Colorado, United States
Novartis Investigative Site
Louisville, Colorado, United States
Novartis Investigative Site
Parker, Colorado, United States
Novartis Investigative Site
Fairfield, Connecticut, United States
Novartis Investigative Site
Hartford, Connecticut, United States
Novartis Investigative Site
Waterbury, Connecticut, United States
Novartis Investigative Site
Dover, Delaware, United States
Novartis Investigative Site
Newark, Delaware, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Bradenton, Florida, United States
Novartis Investigative Site
Clermont, Florida, United States
Novartis Investigative Site
Delray Beach, Florida, United States
Novartis Investigative Site
Doral, Florida, United States
Novartis Investigative Site
Hollywood, Florida, United States
Novartis Investigative Site
Jupiter, Florida, United States
Novartis Investigative Site
Maitland, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Naples, Florida, United States
Novartis Investigative Site
Orlando, Florida, United States
Novartis Investigative Site
Ormond Beach, Florida, United States
Novartis Investigative Site
Panama City, Florida, United States
Novartis Investigative Site
Port Charlotte, Florida, United States
Novartis Investigative Site
Sarasota, Florida, United States
Novartis Investigative Site
Wellington, Florida, United States
Novartis Investigative Site
West Palm Beach, Florida, United States
Novartis Investigative Site
Weston, Florida, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Augusta, Georgia, United States
Novartis Investigative Site
Macon, Georgia, United States
Novartis Investigative Site
Suwanee, Georgia, United States
Novartis Investigative Site
Arlington Heights, Illinois, United States
Novartis Investigative Site
Carbondale, Illinois, United States
Novartis Investigative Site
Flossmoor, Illinois, United States
Novartis Investigative Site
Marywood, Illinois, United States
Novartis Investigative Site
Peoria, Illinois, United States
Novartis Investigative Site
Anderson, Indiana, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
Lafayette, Indiana, United States
Novartis Investigative Site
Merrillville, Indiana, United States
Novartis Investigative Site
Des Moines, Iowa, United States
Novartis Investigative Site
Kansas City, Kansas, United States
Novartis Investigative Site
Lenexa, Kansas, United States
Novartis Investigative Site
Overland Park, Kansas, United States
Novartis Investigative Site
Topeka, Kansas, United States
Novartis Investigative Site
Lexington, Kentucky, United States
Novartis Investigative Site
Lexington, Kentucky, United States
Novartis Investigative Site
Louisville, Kentucky, United States
Novartis Investigative Site
Hammond, Louisiana, United States
Novartis Investigative Site
Auburn, Maine, United States
Novartis Investigative Site
Bangor, Maine, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Bethesda, Maryland, United States
Novartis Investigative Site
Charlotte Hall, Maryland, United States
Novartis Investigative Site
Hagerstown, Maryland, United States
Novartis Investigative Site
Lutherville, Maryland, United States
Novartis Investigative Site
Waldorf, Maryland, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Foxborough, Massachusetts, United States
Novartis Investigative Site
Springfield, Massachusetts, United States
Novartis Investigative Site
Wellesley, Massachusetts, United States
Novartis Investigative Site
Worcester, Massachusetts, United States
Novartis Investigative Site
Caro, Michigan, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
Jackson, Michigan, United States
Novartis Investigative Site
Owosso, Michigan, United States
Novartis Investigative Site
Rochester Hills, Michigan, United States
Novartis Investigative Site
Southfield, Michigan, United States
Novartis Investigative Site
Traverse City, Michigan, United States
Novartis Investigative Site
Edina, Minnesota, United States
Novartis Investigative Site
Golden Valley, Minnesota, United States
Novartis Investigative Site
City of Saint Peters, Missouri, United States
Novartis Investigative Site
Springfield, Missouri, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Great Falls, Montana, United States
Novartis Investigative Site
Hastings, Nebraska, United States
Novartis Investigative Site
Omaha, Nebraska, United States
Novartis Investigative Site
Las Vegas, Nevada, United States
Novartis Investigative Site
Lebanon, New Hampshire, United States
Novartis Investigative Site
Fair Lawn, New Jersey, United States
Novartis Investigative Site
Livingston, New Jersey, United States
Novartis Investigative Site
Somerset, New Jersey, United States
Novartis Investigative Site
West Long Branch, New Jersey, United States
Novartis Investigative Site
Albany, New York, United States
Novartis Investigative Site
Amherst, New York, United States
Novartis Investigative Site
Brooklyn, New York, United States
Novartis Investigative Site
Cedarhurst, New York, United States
Novartis Investigative Site
Johnson City, New York, United States
Novartis Investigative Site
Kingston, New York, United States
Novartis Investigative Site
Lake Success, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Patchogue, New York, United States
Novartis Investigative Site
Plainview, New York, United States
Novartis Investigative Site
Poughkeepsie, New York, United States
Novartis Investigative Site
Staten Island, New York, United States
Novartis Investigative Site
Syracuse, New York, United States
Novartis Investigative Site
The Bronx, New York, United States
Novartis Investigative Site
Asheville, North Carolina, United States
Novartis Investigative Site
Asheville, North Carolina, United States
Novartis Investigative Site
Chapel Hill, North Carolina, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Durham, North Carolina, United States
Novartis Investigative Site
Hickory, North Carolina, United States
Novartis Investigative Site
Raleigh, North Carolina, United States
Novartis Investigative Site
Sanford, North Carolina, United States
Novartis Investigative Site
Wilmington, North Carolina, United States
Novartis Investigative Site
Bismarck, North Dakota, United States
Novartis Investigative Site
Bellevue, Ohio, United States
Novartis Investigative Site
Centerville, Ohio, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Columbus, Ohio, United States
Novartis Investigative Site
Columbus, Ohio, United States
Novartis Investigative Site
Dayton, Ohio, United States
Novartis Investigative Site
Toledo, Ohio, United States
Novartis Investigative Site
Toledo, Ohio, United States
Novartis Investigative Site
Oklahoma City, Oklahoma, United States
Novartis Investigative Site
Oklahoma City, Oklahoma, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Springfield, Oregon, United States
Novartis Investigative Site
Greensburg, Pennsylvania, United States
Novartis Investigative Site
Meadowbrook, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States
Novartis Investigative Site
Willow Grove, Pennsylvania, United States
Novartis Investigative Site
Beaufort, South Carolina, United States
Novartis Investigative Site
Camden, South Carolina, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Greer, South Carolina, United States
Novartis Investigative Site
Mt. Pleasant, South Carolina, United States
Novartis Investigative Site
Old Point Station, South Carolina, United States
Novartis Investigative Site
Spartanburg, South Carolina, United States
Novartis Investigative Site
Spartanburg, South Carolina, United States
Novartis Investigative Site
Knoxville, Tennessee, United States
Novartis Investigative Site
Nashville, Tennessee, United States
Novartis Investigative Site
Nashville, Tennessee, United States
Novartis Investigative Site
Brownwood, Texas, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
Dallas, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Kingwood, Texas, United States
Novartis Investigative Site
Mansfield, Texas, United States
Novartis Investigative Site
San Antonio, Texas, United States
Novartis Investigative Site
Stafford, Texas, United States
Novartis Investigative Site
Sugar Land, Texas, United States
Novartis Investigative Site
Provo, Utah, United States
Novartis Investigative Site
Salt Lake City, Utah, United States
Novartis Investigative Site
Salt Lake City, Utah, United States
Novartis Investigative Site
Alexandria, Virginia, United States
Novartis Investigative Site
Arlington, Virginia, United States
Novartis Investigative Site
Charlottesville, Virginia, United States
Novartis Investigative Site
McLean, Virginia, United States
Novartis Investigative Site
Newport News, Virginia, United States
Novartis Investigative Site
Norfolk, Virginia, United States
Novartis Investigative Site
Richmond, Virginia, United States
Novartis Investigative Site
Richmond, Virginia, United States
Novartis Investigative Site
Vienna, Virginia, United States
Novartis Investigative Site
Winchester, Virginia, United States
Novartis Investigative Site
Richland, Washington, United States
Novartis Investigative Site
Spokane, Washington, United States
Novartis Investigative Site
Tacoma, Washington, United States
Novartis Investigative Site
Wenatchee, Washington, United States
Novartis Investigative Site
Beckley, West Virginia, United States
Novartis Investigative Site
Huntington, West Virginia, United States
Novartis Investigative Site
Green Bay, Wisconsin, United States
Novartis Investigative Site
Milwaukee, Wisconsin, United States
Novartis Investigative Site
Monroe, Wisconsin, United States
Novartis Investigative Site
Neenah, Wisconsin, United States
Novartis Investigative Site
Wisconsin Rapids, Wisconsin, United States
Novartis Investigative Site
Casper, Wyoming, United States
Novartis Investigative Site
Jenin, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Buenos Aires, , Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, , Argentina
Novartis Investigative Site
Córdoba, , Argentina
Novartis Investigative Site
Salta, , Argentina
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Saint John, New Brunswick, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Guelph, Ontario, Canada
Novartis Investigative Site
Kingston, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Saint Catharine's, Ontario, Canada
Novartis Investigative Site
Chicoutimi, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Trois-Rivières, Quebec, Canada
Novartis Investigative Site
Santiago, , Chile
Novartis Investigative Site
Guadalajara, Jalisco, Mexico
Novartis Investigative Site
Monterrey, Nuevo León, Mexico
Novartis Investigative Site
Culiacan, State of Mexico, Mexico
Novartis Investigative Site
Distrito Federal, , Mexico
Novartis Investigative Site
Guaynabo, , Puerto Rico
Novartis Investigative Site
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFTY720D2403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.